科兴生物制药股份有限公司 审计报告 大华审字[2024]0011002785 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 您可使用手机"扫一扫"或进入"注册会计师行业统一些答题公 "。 " … … · 科兴生物制药股份有限公司 审计报告及财务报表 (2023 年 1 月 1 日至 2023 年 12 月 31 日止） | E | 求 | 页 次 | | --- | --- | --- | | 审计报告 r | | 1-6 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | 4 | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-12 | | 财务报表附注 | | 1-97 | . :: 1 北京市海淀区西四五中路 16号院 7号楼 ...

科兴生物制药股份有限公司 内部控制审计报告 大华内字[2024]0011000115 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 科兴生物制药股份有限公司 内部控制审计报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 www.dahua-cpa.com 内 部 控 制 审 计 报 告 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 第 1 页 大华内字[2024]0011000115 号 科兴生物制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准 ...

Financial Performance - The company reported a profit distribution plan for 2023, which includes no cash dividends, no stock bonuses, and no capital reserve transfers to increase share capital [5]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges [4]. - The company's operating revenue for 2023 was approximately ¥1,259 million, a decrease of 4.32% compared to ¥1,316 million in 2022 [21]. - The net profit attributable to shareholders was a loss of approximately ¥190 million in 2023, compared to a loss of ¥90 million in 2022 [21]. - The basic earnings per share for 2023 was -¥0.96, down from -¥0.45 in 2022 [22]. - The weighted average return on equity decreased to -11.11% in 2023, down from -4.87% in 2022, a decline of 6.24 percentage points [23]. - The net cash flow from operating activities was a negative ¥87 million in 2023, compared to a negative ¥86 million in 2022 [21]. - The company's total assets at the end of 2023 were approximately ¥3,031 million, a decrease of 4.22% from ¥3,165 million at the end of 2022 [21]. - The company reported a total of 1,091,415 shares held at the end of the reporting period, with no changes in shareholding during the year [154]. - The company reported a total revenue of ¥1,259,035,602.11, a decrease of 4.32% compared to the same period last year [84]. Research and Development - Research and development expenses accounted for 27.39% of operating revenue in 2023, an increase of 12.70 percentage points from 14.69% in 2022 [23]. - The company has introduced 12 new products, focusing on key oncology areas, including six major products for breast cancer treatment [34]. - The company’s R&D expenses reached RMB 344.80 million, a year-on-year increase of 78.38%, accounting for 27.39% of total revenue [38]. - The company has initiated 10 innovative drug projects focused on key disease areas, with several projects entering the process development stage [66]. - The company has achieved the creation of 6 innovative drugs during the reporting period, demonstrating strong in vitro activity and specificity compared to peers [58]. - The company is focusing on innovative biotechnologies such as CRISPR-Cas gene editing, mRNA drugs, and artificial intelligence, which are expected to reshape the pharmaceutical industry [55]. - The company has completed process validation for its albumin paclitaxel production line and interferon production line, with the interferon line obtaining GMP certification [42]. - The company has established a comprehensive biopharmaceutical innovation research and development system, focusing on unmet clinical needs in oncology, immunology, and degenerative diseases [118]. - The company has 163 R&D personnel, representing 15.58% of the total workforce, with an average salary of ¥31.34 thousand, an increase from ¥27.53 thousand in the previous period [70]. Market and Sales - The company has established a marketing distribution network covering nearly 22,700 various terminal points in the domestic market [50]. - The company has expanded its marketing network to approximately 22,700 medical institutions, a 13.5% increase from the previous year, including over 7,500 hospitals [46]. - The market share of the company's "Sairuo Jin®" short-acting interferon injection remains the highest in China [41]. - The company has established a comprehensive overseas commercialization platform covering over 40 countries, with significant growth in emerging markets [34]. - The company achieved total revenue of RMB 1,259.04 million in 2023, a slight decrease year-on-year [33]. - The company is actively pursuing international collaborations and has established strategic partnerships with several pharmaceutical companies for the commercialization of key drugs [45]. - The company has signed cooperation agreements with Beijing Yabao Pharmaceutical and Zhengda Tianqing Pharmaceutical, obtaining exclusive agency rights for Sorafenib and commercial rights for Palbociclib in multiple countries [48]. Governance and Compliance - The audit report issued by Da Hua Certified Public Accountants confirmed the financial statements' accuracy and completeness [5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties [7]. - There are no violations of decision-making procedures regarding external guarantees [7]. - The company has not disclosed any special arrangements for corporate governance [8]. - The company has established a sound organizational structure, ensuring independence in operations, assets, personnel, and finance from the controlling shareholder [147]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors, and has received an award for excellent practice in annual report performance presentation [148]. - The board of directors and supervisory board operate independently, effectively reducing operational risks and safeguarding the rights of shareholders [147]. - The company has received recognition for its effective governance practices, aligning with legal and regulatory requirements [148]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report's risk factors section [4]. - The company has a comprehensive risk statement regarding forward-looking statements, advising investors to be cautious [6]. - The company faces risks related to core personnel turnover, potential leakage of trade secrets, and reliance on overseas suppliers for key raw materials [76][77]. - The company continues to maintain a leading position in domestic niche markets despite a slight decline in revenue due to regional procurement impacts, with ongoing clinical trials for multiple R&D projects [82]. Future Outlook - The company aims to accelerate its internationalization strategy, focusing on maximizing product commercialization value in emerging markets [140]. - The company plans to push forward with clinical trials for 4 projects and submit IND applications for 2 projects, aiming to enhance its innovative drug pipeline [141]. - The company intends to explore external licensing and collaboration to maximize the commercial value of self-developed products [142]. - The company plans to submit at least 6 invention patents in 2024 as part of its commitment to innovation [141]. - The company aims to enhance operational efficiency through intelligent management and lean practices, targeting cost reduction and efficiency improvement [143]. - Future guidance includes maintaining a net profit margin of at least 15% for the upcoming fiscal year [162].

Financial Performance - The company's revenue for Q1 2024 was CNY 360,663,523.23, representing an increase of 11.79% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 12,403,443.45, with a basic earnings per share of CNY 0.06[5]. - Operating profit for Q1 2024 was ¥15,841,847.71, a significant recovery from a loss of ¥17,131,632.71 in Q1 2023[18]. - Net profit for Q1 2024 amounted to ¥11,488,257.28, compared to a net loss of ¥9,859,490.11 in the same period last year[18]. - The company reported a basic and diluted earnings per share of ¥0.06 for Q1 2024, recovering from a loss of ¥0.04 per share in Q1 2023[19]. - Total revenue for Q1 2024 reached ¥360,663,523.23, an increase from ¥322,637,429.95 in Q1 2023, representing a growth of approximately 11.5%[17]. Cash Flow - The net cash flow from operating activities was negative CNY 6,224,291.11[5]. - In Q1 2024, the cash inflow from operating activities totaled $290.48 million, a decrease of 10% compared to $322.68 million in Q1 2023[22]. - The net cash flow from operating activities was -$6.22 million, improving from -$46.60 million in the same quarter last year[22]. - The company reported a total cash outflow from operating activities of $296.71 million, down from $369.28 million in Q1 2023[22]. - Cash inflow from investment activities was $393.45 million, up from $362.08 million in Q1 2023, primarily due to an increase in cash received from investments[22]. - The net cash flow from investment activities was -$224.08 million, an improvement from -$296.15 million year-over-year[22]. - Cash inflow from financing activities was $113.77 million, down from $158.81 million in Q1 2023[23]. - The net cash flow from financing activities was $16.59 million, a decrease from $41.55 million in the previous year[23]. - The ending cash and cash equivalents balance was $346.87 million, down from $482.27 million at the end of Q1 2023[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,063,870,549.81, an increase of 1.08% from the previous year[6]. - Total assets increased to ¥3,063,870,549.81 in Q1 2024, up from ¥3,031,093,090.30 in Q1 2023[16]. - Total liabilities rose to ¥1,439,998,995.98 in Q1 2024, compared to ¥1,400,297,996.60 in Q1 2023, indicating a growth of approximately 2.9%[16]. - The total current assets as of March 31, 2024, amounted to RMB 1,160,746,557.13, an increase from RMB 1,133,624,217.10 as of December 31, 2023, reflecting a growth of approximately 2.4%[14]. - The total non-current assets were reported at RMB 1,455,000,000.00, with fixed assets valued at RMB 933,578,508.87, up from RMB 804,691,512.56, reflecting an increase of approximately 16%[14]. Shareholder Information - The company reported a total of 131,778,347 shares held by its largest shareholder, accounting for 66.15% of the total shares[11]. - The second-largest shareholder, 邓学勤, holds 1,764,125 shares, representing 0.89% of the total shares[11]. - As of March 31, 2024, the "科兴生物制药股份有限公司回购专用证券账户" held 1,308,172 shares, accounting for 0.66% of the total shares[12]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[13]. Research and Development - Research and development expenses totaled CNY 35,207,355.05, accounting for 9.76% of revenue, a decrease of 5.31 percentage points year-on-year[6]. - Research and development expenses decreased to ¥35,207,355.05 in Q1 2024 from ¥48,607,343.41 in Q1 2023, a reduction of about 27.5%[18]. - The company has committed to deepening lean management across all business processes to enhance operational efficiency[8]. Operational Efficiency - The company achieved a significant increase in domestic sales volume, with a 26% year-on-year growth in self-owned product sales[8]. - The company reported a decrease in sales and production costs compared to the previous year, contributing to improved operational efficiency[8]. - Non-recurring gains totaled CNY 2,330,255.09, with government subsidies and asset disposal gains included[8]. - The company’s cash flow statement for Q1 2024 is currently unaudited, indicating ongoing financial assessments[20]. Other Information - The company has not disclosed any significant new strategies or product developments during this reporting period[13]. - The company paid $54.88 million to employees, a decrease from $65.72 million in Q1 2023[22]. - The company received $391 million from investment recoveries, compared to $360 million in the same period last year[22].

会议由董事长邓学勤主持，公司监事，部分高管列席会议。会议召开符合有 关法律、法规、规章和《公司章程》的规定，会议决议合法、有效。 证券代码：688136 证券简称：科兴制药 公告编号：2024-020 科兴生物制药股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会第十四次会议 于 2024 年 4 月 25 日在深圳市南山区科兴科学园 D1 栋 43 楼会议室以现场结合 通讯的方式召开。本次会议通知于 2024 年 4 月 21 日通过邮件的方式送达各位董 事。本次会议应出席董事 7 人，实际出席董事 7 人。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司 2023 年度董事会工作报告的议案》 报告期内，公司董事会严格依照《公司法》《证券法》《科兴制药股份有限 公司公司章程》以及《科兴生物制药股份有限公司董事会议事规则》等相关法律 法规和公司规章制度所赋 ...

| 第一章 | 总则 2 | | --- | --- | | 第二章 | 监事会职权 2 | | 第三章 | 会议召集与主持 3 | | 第四章 | 会议提案 4 | | 第五章 | 会议通知 5 | | 第六章 | 会议规则 5 | | 第七章 | 会议纪律 7 | | 第八章 | 附则 8 | 科兴生物制药股份有限公司 二〇二四年四月 监事会议事规则 （修订稿） 科兴生物制药股份有限公司监事会议事规则 第一章 总则 第一条 为了规范科兴生物制药股份有限公司（以下简称"公司"）监事会的 议事程序和行为，确保监事会公平、公正、高效运作和有效履行监督职能，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》、《上市公司治理准则》、《上海证券交易所科创板股票上市规则》（以下 简称"《科创板上市规则》"）等法律、法规、规范性文件和《科兴生物制药股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，特制订本规则。 第二条 本规则对公司全体监事具有约束力。 第二章 监事会职权 第三条 公司设监事会，监事会对股东大会负责。 第四条 根据《公司章程》规定，监事会由三名监事组成，其中至少 ...

科兴生物制药股份有限公司 审计委员会对会计师事务所 2023 年度履行监督职责情 况的报告 科兴生物制药股份有限公司（以下简称"公司"）聘请大华会计师事务所（特 殊普通合伙）作为公司 2023 年度财务报告及内部控制审计机构。 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁 布的《国有企业、上市公司选聘会计师事务所管理办法》，公司审计委员会切实 对大华会计师事务所（特殊普通合伙）在 2023 年度的审计工作情况履行了监督 职责。具体情况如下： 截至 2023 年年末，大华会计师事务所（特殊普通合伙）共有合伙人 270 人； 注册会计师 1471 人；其中签署过证券服务业务审计报告的注册会计师 1,141 人。 2022 年度的收入总额为 332,731.85 万元；审计业务收入 307,355.10 万元；证券 业务收入 138,862.04 万元。（以上数据已经审计）。2022 年度上市公司审计客户 家数：488 家，主要行业：制造业、信息传输软件和信息技术服务业、批发和零 售业、房地产业、建筑业，2022 年度上市公司年报审计收费总额：61,034.29 万 元，本公司同行业上市公司审 ...

科兴生物制药股份有限公司 关于营业收入扣除事项的 专项核查意见 大华核字[2024]0011005692 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 科兴生物制药股份有限公司 关于营业收入扣除事项的 专项核查意见 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | 一、 | 关于营业收入扣除事项的专项核查意见 | | 1-2 | | | --- | --- | --- | --- | --- | | 二、 | 目 营业收入扣除情况明细表 | 录 | 页 1-2 | 次 | 一、管理层对明细表的责任 管理层负责按照监管机构上市规则及相关要求的规定编制明细表 以满足监管要求，并负责设计、执行和维护必要的内部控制，以使明 细表不存在由于舞弊或错误导致的重大错报。 二、注册会计师的责任 第 1 页 大华核字[2024]0011005692 号专项核查意见 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-026 科兴生物制药股份有限公司 关于终止 2023 年度向特定对象发行 A 股股票事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）于2024年4月25日召开第二 届董事会第十四次会议、第二届监事会第十三次会议，审议通过了《关于终止2023 年度向特定对象发行A股股票事项的议案》。现将有关情况公告如下。 一、2023年度向特定对象发行A股股票事项的基本情况 公司于2023年7月24日召开了第二届董事会第八次会议、第二届监事会第八 次会议，于2023年8月10日召开了2023年第二次临时股东大会，审议通过了《关 于公司2023年度向特定对象发行A股股票方案的议案》等相关议案，同意公司向 特定对象发行股票事项，并授权公司董事会办理本次向特定对象发行股票相关事 宜。截至目前，公司尚未向上海证券交易所、中国证监会提交相关申请材料。 二、终止2023年度向特定对象发行A股股票事项的原因 自公司2023年度向特定对象 ...

科兴生物制药股份有限公司 董事会审计委员会工作细则 第一章 总 则 第一条 为强化科兴生物制药股份有限公司（以下简称"公司"）董事会决策功能， 健全董事会的审计评价和监督机制，确保董事会对经理层的有效监督，进一步完 善公司治理结构，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司治理准则》、《上市公司独立董事管理办法》、《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》、《科兴生物制药股份有限公 司章程》（以下简称"《公司章程》"）及其他有关规定，公司设立董事会审计委 员会，并制定本工作细则。 第二条 董事会审计委员会是董事会下设的专门工作机构，协助董事会开展相关 工作，向董事会报告工作并对董事会负责，以及与内外部审计的独立沟通、监督 和核查工作。 科兴生物制药股份有限公司 董事会审计委员会工作细则 2024 年 4 月 | 第一章 | 总 则 1 | | --- | --- | | 第二章 | 人员组成 1 | | 第三章 | 职责权限 2 | | 第四章 | 决策程序 4 | | 第五章 | 议事规则 5 | | 第六章 | 附则 7 | 第三条 审计委员会根据《公司 ...